Literature DB >> 16084096

CREB: the unindicted cancer co-conspirator.

Michael D Conkright1, Marc Montminy.   

Abstract

The transcription factor cAMP response-element binding protein (CREB) participates in a diverse array of cellular processes, including survival, proliferation and glucose metabolism. A new report by Shankar et al. shows that patients with acute myeloid leukemia (AML) have a greater incidence of relapse when intracellular levels of CREB are elevated. By enhancing expression of certain cell-cycle genes, CREB appears to promote growth-factor-independent proliferation and survival of myeloid cells. The results provide new insights into CREB function and suggest potential avenues for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16084096     DOI: 10.1016/j.tcb.2005.07.007

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  56 in total

1.  Targeting CREB for cancer therapy: friend or foe.

Authors:  Xiangshu Xiao; Bingbing X Li; Bryan Mitton; Alan Ikeda; Kathleen M Sakamoto
Journal:  Curr Cancer Drug Targets       Date:  2010-06       Impact factor: 3.428

2.  Synaptic activity-responsive element (SARE): A unique genomic structure with an unusual sensitivity to neuronal activity.

Authors:  Masatoshi Inoue; Nan Yagishita-Kyo; Mio Nonaka; Takashi Kawashima; Hiroyuki Okuno; Haruhiko Bito
Journal:  Commun Integr Biol       Date:  2010-09

3.  Upstream AP1- and CREB-binding sites confer high basal activity on the adeno-associated virus type 5 capsid gene promoter.

Authors:  Chaoyang Ye; David J Pintel
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

4.  TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation.

Authors:  Ali I Kuraishy; Samuel W French; Mara Sherman; Marco Herling; Dan Jones; Randolph Wall; Michael A Teitell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

5.  Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma.

Authors:  James R Cerhan; Stephen M Ansell; Zachary S Fredericksen; Neil E Kay; Mark Liebow; Timothy G Call; Ahmet Dogan; Julie M Cunningham; Alice H Wang; Wen Liu-Mares; William R Macon; Diane Jelinek; Thomas E Witzig; Thomas M Habermann; Susan L Slager
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

6.  The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin.

Authors:  Reuben J Shaw; Katja A Lamia; Debbie Vasquez; Seung-Hoi Koo; Nabeel Bardeesy; Ronald A Depinho; Marc Montminy; Lewis C Cantley
Journal:  Science       Date:  2005-11-24       Impact factor: 47.728

Review 7.  RSK isoforms in cancer cell invasion and metastasis.

Authors:  Florian J Sulzmaier; Joe W Ramos
Journal:  Cancer Res       Date:  2013-10-04       Impact factor: 12.701

8.  Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract.

Authors:  Addanki P Kumar; Shylesh Bhaskaran; Manonmani Ganapathy; Katherine Crosby; Michael D Davis; Peter Kochunov; John Schoolfield; I-Tien Yeh; Dean A Troyer; Rita Ghosh
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

9.  CREB trans-activation of disruptor of telomeric silencing-1 mediates forskolin inhibition of CTGF transcription in mesangial cells.

Authors:  Zhiyuan Yu; Qun Kong; Bruce C Kone
Journal:  Am J Physiol Renal Physiol       Date:  2010-01-06

10.  Growth suppression of lung cancer cells by targeting cyclic AMP response element-binding protein.

Authors:  Sita Aggarwal; Seung-Wook Kim; Seung-Hee Ryu; Wen-Cheng Chung; Ja Seok Koo
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.